Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "hold" rating to a "sell" rating in a report released on Friday.

Several other analysts also recently weighed in on AGIO. Leerink Partnrs downgraded Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 27th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Scotiabank raised their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a "sector outperform" rating in a report on Friday. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $52.33.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO traded up $0.44 during trading on Friday, hitting $44.87. 672,837 shares of the company's stock traded hands, compared to its average volume of 689,661. Agios Pharmaceuticals has a 12-month low of $20.40 and a 12-month high of $53.28. The stock has a fifty day moving average of $44.62 and a two-hundred day moving average of $42.13. The firm has a market cap of $2.55 billion, a P/E ratio of -6.90, a PEG ratio of 0.47 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The business had revenue of $8.60 million for the quarter, compared to analysts' expectations of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. Agios Pharmaceuticals's quarterly revenue was up 28.4% on a year-over-year basis. During the same period last year, the firm posted ($1.51) earnings per share. As a group, analysts expect that Agios Pharmaceuticals will post 7.54 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company's stock, valued at $988,346.74. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian Goff sold 11,091 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently made changes to their positions in the company. Nordea Investment Management AB increased its stake in Agios Pharmaceuticals by 13.0% in the first quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company's stock worth $7,824,000 after purchasing an additional 30,764 shares during the period. Caxton Associates LP bought a new stake in Agios Pharmaceuticals during the 1st quarter valued at $1,087,000. Vanguard Group Inc. lifted its holdings in shares of Agios Pharmaceuticals by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company's stock worth $123,096,000 after buying an additional 59,851 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of Agios Pharmaceuticals by 87.3% in the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company's stock valued at $29,245,000 after acquiring an additional 316,100 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company's stock worth $58,861,000 after acquiring an additional 388,381 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.